High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk. The IDEAL and EPIC-Norfolk Studies

Journal of the American College of Cardiology

Volumn 51, Issue 6, 2008, Pages 634-642

  van der Steeg, Wim A ^a   Holme, Ingar ^b   Boekholdt, S Matthijs ^a   Larsen, Mogens Lytken ^c   Lindahl, Christina ^d   Stroes, Erik S G ^a   Tikkanen, Matti J ^e   Wareham, Nicholas J ^f   Faergeman, Ole ^c   Olsson, Anders G ^g   Pedersen, Terje R ^b   Khaw, Kay Tee ^h   Kastelein, John J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c Department of Medicine Cardiology A ^*  (Denmark)

^d Pfizer Sweden   (Sweden)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL;

EID: 38749102779     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.09.060     Document Type: Article

References (26)

1. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., and Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256 (1986) 2835-2838
2. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
3. Barter P.J., and Rye K.A. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 259 (2006) 447-454
4. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
5. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
6. Yvan-Charvet L., Matsuura F., Wang N., et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 27 (2007) 1132-1138
7. Ishigami M., Yamashita S., Sakai N., et al. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem (Tokyo) 116 (1994) 257-262
8. Kontush A., Chantepie S., and Chapman M.J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23 (2003) 1881-1888
9. Pedersen T.R., Faergeman O., Kastelein J.J.P., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL Study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
10. Day N., Oakes S., Luben R., et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 80 Suppl 1 (1999) 95-103
11. Albers J.J., Marcovina S.M., and Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 38 (1992) 658-662
12. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48 (2002) 171-180
13. Luc G., Bard J.M., Ferrieres J., et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 22 (2002) 1155-1161
14. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104 (2001) 1108-1113
15. Chapman M.J. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 111 (2006) 893-908
16. Cheung M.C., Brown B.G., Wolf A.C., and Albers J.J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 32 (1991) 383-394
17. Berard A.M., Foger B., Remaley A., et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 3 (1997) 744-749
18. Trigatti B.L., Krieger M., and Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 1732-1738
19. Moerland M., Samyn H., van Gent T., et al. Atherogenic, enlarged, and dysfunctional HDL in human PLTP/ApoA-I double transgenic mice. J Lipid Res 48 (2007) 2622-2631
20. Tall A.R., Costet P., and Wang N. Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest 110 (2002) 899-904
21. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., and Fogelman A.M. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2 (2006) 504-511
22. Lee J.Y., and Parks J.S. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 16 (2005) 19-25
23. Navab M., Hama S.Y., Anantharamaiah G.M., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41 (2000) 1495-1508
24. Forrester J.S., and Shah P.K. Emerging strategies for increasing high-density lipoprotein. Am J Cardiol 98 (2006) 1542-1549
25. Birjmohun R.S., Hutten B.A., Kastelein J.J., and Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 (2005) 185-197
26. Sacks F.M., Tonkin A.M., Shepherd J., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102 (2000) 1893-1900